TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress

Tuesday, September 06, 2022

Tyra Biosciences, Inc., a precision oncology company, has announced that they will be presenting preclinical data on their therapeutic candidate, TYRA-300, at the European Society for Medical Oncology (ESMO) 2022 Congress. The congress will take place in Paris, France from September 9-13, 2022. The company aims to develop purpose-built therapies that can overcome tumor resistance and improve outcomes for cancer patients.

According to Todd Harris, the CEO of Tyra Biosciences, the preclinical data being presented at the ESMO Congress demonstrates the enhanced anti-tumor activity and selectivity of TYRA-300 compared to other agents in its class. The promising results support the further development of TYRA-300, and the company plans to initiate its SURF301 Phase 1/2 study in the near future.

The details of the poster presentation are as follows:

Title: TYRA-300: FGFR3 selective and gatekeeper agnostic Presenter: Jacqueline Starrett Date: Monday, September 12, 2022 Session: Developmental therapeutics Presentation Number: 462P

Regular abstracts will be published on the ESMO website on September 5, 2022. The poster presentation on TYRA-300 will be available on the Tyra Biosciences website under the "For Investors" section on September 12, 2022.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit